With a promising patented technology Cerebrum Matter has taken-up the challenge to make treatment of symptoms available for the fast growing population of 50 million people world wide that live with dementia.
The estimated health cost will rise to a staggering $2 trillion by 2030. Currently there is no cure and or effective treatment available. The quality of live of the patients involved and their families is impacted from day one.
There is a need for individualized therapies, due to the variety of disease progression patterns. The failure of applying drugs effectively at a high cost is driving the search for alternatives.
Playing individualized games seems the recipe for success. Artificial Intelligence ensures the stimulation of the brain in the areas affected. With Neuro feedback, valuable data is generated and insight is provided into the workings of the brain. The latter helps improving the therapy and understanding of the disease.
With 90 clinical trials with dementia patients successfully completed and 15 NHS clinical professionals validating the need for early intervention, important milestones have been achieved in the roadmap to a global roll-out.